Daptomycin Concentration in Drainage Fluid and Blood Samples of ICU Patients

Completed

• Conditions: Heart Assist Device

• Registration Number: NCT03004066
• Lead Sponsor: University Hospital Tuebingen

Brief Summary

10 patients with chronic heart failure receiving daptomycin therapy after implantation of a left ventricular heart assist system. Measurement of daptomycin levels in drainage fluids (mediastinal and pleural drainage systems) and in blood samples.

Detailed Description

Not available

Study Timeline

• Study Start: 2016-10
• Study First Submitted: 2016-11-16
• Study First Submitted QC: 2016-12-21
• Study First Posted: 2016-12-28
• Status Verified: 2018-04
• Primary Completion: 2019-03-31
• Study Completion: 2019-03-31
• Last Update Submitted: 2019-04-18
• Last Update Posted: 2019-04-19

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 9

Inclusion Criteria

• written consent
• heart assist device implantation
• wound drainage
• daptomycin therapy

Exclusion Criteria

• pregnancy
• no written consent possible
• absence of wound drainage
• allergy to study medication
• acute rhabdomyolysis

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
levels of Daptomycin in drainage fluid	4 days	Pharmacokinetics of Daptomycin in intensive care patients with wound drainage after surgery (LVAD implantation)
levels of Daptomycin in blood samples	4 days	Pharmacokinetics of Daptomycin in intensive care patients after surgery (LVAD implantation)

Secondary Outcome Measures

Name	Time	Method
infections	14 days	incidence of gram-positive infections

Trial Locations

Locations (1)

University Hospital Tuebingen; 🇩🇪 Tuebingen, Germany